达英-35（醋酸环丙孕酮）：安全性问题。 - Suppr

Suppr

超能文献

Diane-35 (cyproterone acetate): safety concerns.

作者信息

Wooltorton Eric

出版信息

CMAJ. 2003 Feb 18;168(4):455-6.

PMID:12591790

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC143555/

Abstract

摘要

相似文献

Diane-35 (cyproterone acetate): safety concerns.

CMAJ. 2003 Feb 18;168(4):455-6.

First-use risks.

CMAJ. 2003 May 27;168(11):1394.

Too much disclosure of product risks? CBC television, SOGC, and Diane-35.

J Obstet Gynaecol Can. 2003 Apr;25(4):268-9; discussion 270-3. doi: 10.1016/s1701-2163(16)31028-3.

[Oral contraceptives, risks and hazards].

Ann Dermatol Venereol. 2014 Jan;141(1):5-6. doi: 10.1016/j.annder.2013.12.001. Epub 2014 Jan 10.

[Suspension of Diane35 and its generics: an over-reaction by the French National Medicines Agency (ANSM) unfounded in the light of proven or accepted medical knowledge].

Ann Dermatol Venereol. 2013 Jun-Jul;140(6-7):474-8. doi: 10.1016/j.annder.2013.04.093. Epub 2013 May 31.

Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.

Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):427-36. doi: 10.1002/pds.896.

Specific oral contraceptive use and venous thromboembolism resulting in hospital admission.

N Z Med J. 2004 Nov 26;117(1206):U1176.

Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.

J Obstet Gynaecol Can. 2004 May;26(5):457-8.

Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.

J Obstet Gynaecol Can. 2004 Jun;26(6):549-50. doi: 10.1016/s1701-2163(16)30371-1.

[Pill matters: targeted research into side effects necessary].

Ned Tijdschr Geneeskd. 2014;158:A7740.

引用本文的文献

Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke.

CMAJ. 2014 Jun 10;186(9):690-3. doi: 10.1503/cmaj.130579. Epub 2014 Feb 3.

Examining the use of oral contraceptives in the management of acne.

Int J Womens Health. 2010 Aug 9;2:69-76. doi: 10.2147/ijwh.s5915.

Medicine by media: did a critical television documentary affect the prescribing of cyproterone--estradiol (Diane-35)?

CMAJ. 2005 Nov 22;173(11):1313-5. doi: 10.1503/cmaj.050567.

First-use risks.

CMAJ. 2003 May 27;168(11):1394.

本文引用的文献

The effect of factor V Leiden carriage on maternal and fetal health.

CMAJ. 2002 Jul 9;167(1):48-54.

Oral contraceptives and myocardial infarction.

CMAJ. 2002 Apr 2;166(7):931.

Oral contraceptives and venous thromboembolism: a five-year national case-control study.

Contraception. 2002 Mar;65(3):187-96. doi: 10.1016/s0010-7824(01)00307-9.

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

Lancet. 2001 Oct 27;358(9291):1427-9. doi: 10.1016/S0140-6736(01)06522-9.

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

BMJ. 2001 Jul 21;323(7305):131-4. doi: 10.1136/bmj.323.7305.131.

Oral contraceptives and the risk of venous thrombosis.

N Engl J Med. 2001 May 17;344(20):1527-35. doi: 10.1056/NEJM200105173442007.

Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.

BMJ. 2000 Nov 11;321(7270):1190-5. doi: 10.1136/bmj.321.7270.1190.

Third generation oral contraceptives.

BMJ. 2000 Jul 22;321(7255):190-1. doi: 10.1136/bmj.321.7255.190.

Oral contraceptives and fatal pulmonary embolism.

Lancet. 2000 Jun 17;355(9221):2133-4. doi: 10.1016/S0140-6736(00)02382-5.

Oral contraceptives and risk of venous thromboembolism: impact of duration of use.

Contraception. 1998 Jan;57(1):61-5. doi: 10.1016/s0010-7824(97)00209-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验